MHA 707 | Medicines, Devices & Innovation in U.S. Healthcare | 30+ Questions on Biologics, FDA Approval, DEA Schedules, IP Law | Louisiana State University Shreveport

This document contains a high-quality and verified set of over 30 exam questions with correct answers for MHA 707 – Medicines, Devices, and Technology, focused on Chapter 4, from the 2025/2026 academic year at Louisiana State University Shreveport (LSUS). It offers a comprehensive review of how pharmaceutical drugs, medical devices, and healthcare technologies are developed, regulated, priced, and integrated into the U.S. healthcare system. Topics covered include: – Definitions and distinctions between pharmaceuticals, medical equipment, medical supplies, and biologics – Approval processes such as the New Drug Application (NDA) and FDA device classifications (Class I–III) – DEA Drug Schedules, controlled substance regulation, and abuse potential – High-level concepts like Operation Warp Speed, intellectual property protection, and the development of generics and biosimilars – Market and cost considerations, including specialty drugs, pricing challenges, physician preference items, and total spending on OTCs and devices – The structure of the medical device and pharma industry, and barriers to cost mitigation in innovation-heavy sectors This document serves as a strong resource for understanding the clinical, regulatory, and financial dynamics that surround therapeutic goods and technologies in modern healthcare. Best suited for: – Graduate students in Healthcare Administration, Health Law & Policy, Public Health, or Health Technology Management – Healthcare professionals engaged in technology adoption, procurement, regulatory compliance, or pharmaceutical strategy – Learners preparing for MHA 707 at LSUS, or those in comparable courses exploring the role of innovation and devices in healthcare delivery Keywords: pharmaceuticals, medical devices, FDA approval, DEA drug schedules, biologics, generics, biosimilars, intellectual property, NDA, medical supplies, pricing of drugs, specialty medications, OTC drug spending, healthcare innovation, Operation Warp Speed, device regulation, physician preference items, healthcare technology costs, drug development process